The Monarch eTNS® System is the First FDA Cleared Device for Treating Pediatric ADHD.
The Monarch eTNS System is indicated for the treatment of pediatric Attention Deficit Hyperactivity Disorder (ADHD) as a monotherapy in patients ages 7 through 12 years old who are not currently taking prescription ADHD medications. The device is used for patient treatment by prescription only and is intended to be used in the home under the supervision of a caregiver during periods of sleep.
The most common side effects observed with eTNS use are: drowsiness, an increase in appetite, trouble sleeping, teeth clenching, headache and fatigue. No serious adverse events have been associated with use of the device. Please consult the instructions for use for additional information.
Latest News
January 13, 2025 Clinical Trial of NeuroSigma's Monarch eTNS System for ADHD at King's College London Completes Enrollment
December 11, 2024 New Clinical Trial of eTNS for Pediatric ADHD to Commence at Denmark's Center for Evidence-Based Psychiatry
May 09, 2024 NeuroSigma Announces Acceptance into 2024 Cohort of the KidsX Accelerator Program
January 18, 2024 NeuroSigma Announces FDA Clearance of its Second-Generation Monarch eTNS System for Treating Pediatric ADHD
November 07, 2023 NeuroSigma Announces FDA 510(k) Submission for Second Generation Monarch eTNS System
October 03, 2023 NeuroSigma Announces HSA Approval of the Monarch eTNS System in Singapore
July 12, 2023 NeuroSigma Establishes Singapore Subsidiary
March 01, 2023 NeuroSigma Announces New Telehealth Option for Patients and Caregivers Interested in eTNS for Pediatric ADHD
January 31, 2023 NeuroSigma Announces Strategic Digital Marketing Partnership with Data360
November 08, 2022 NeuroSigma Announces that Enrollment Commences in Two Large, Double-Blind Trials of eTNS for Pediatric ADHD
